Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

Company Announcement COPENHAGEN, Denmark; October 23, 2026

Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart sesutecan (Rina-S^{®}) compared to investigator’s choice chemotherapy

Results demonstrated statistically significant and clinically meaningful improvement in PFS and OS in patients with platinum-resistant ovarian cancer (PROC)

Data will be submitted for presentation at a future medical meeting and discussed with regulatory authorities worldwide Genmab A/S (Nasdaq: GMAB) announced today positive topline results from the global Phase 3 RAINFOL™-02 trial of rinatabart sesutecan (Rina-S^{®}), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), in patients with platinum-resistant ovarian cancer (PROC) regardless of FRα expression level or prior treatment with mirvetuximab. The trial met its primary endpoint of progression-free survival (PFS), with Rina-S demonstrating a statistically significant and clinically meaningful improvement compared with investigator’s choice chemotherapy in the intent-to-treat (ITT) and in the primary analysis set (PAS) populations. The ITT population (N=584) comprised of all randomized patients with PROC, regardless of FRα expression. The PAS population (N=492) mandated patients with FRα expression ≥75% PS2+ to have been treated with mirvetuximab. In the ITT population, Rina-S demonstrated a 71% reduction in the risk of disease progression or death (HR 0.29; 95% CI, 0.23-0.37; p<0.0001). In the PAS population, Rina-S demonstrated a 67% reduction in the risk of disease progression or death (HR 0.33; 95% CI, 0.26–0.42; p<0.0001). The study also met its key secondary endpoint of overall survival (OS), demonstrating a statically significant and clinically meaningful improvement in the ITT population (HR 0.43; 95% CI, 0.31–0.59; p<0.0001) and in the PAS population (HR 0.44; 95% CI, 0.31–0.63; p<0.0001). The observed safety profile was consistent with the known profile of Rina-S, with no new safety signals or unexpected safety concerns identified. “As the first Phase 3 readout from our Rina-S program, the positive topline results from RAINFOL-02 mark a significant milestone for Genmab and strengthen our confidence in Rina-S’s potential for patients with platinum-resistant ovarian cancer. These results advance our ambition to become a leader in gynecologic oncology and reflect our commitment to improving the lives of patients with high unmet medical needs,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “We look forward to discussing these results and potential next steps with regulatory authorities worldwide. We are deeply grateful to the patients, caregivers, and investigators whose participation made this study possible.” Based on these results, Genmab plans to engage with regulatory authorities worldwide regarding potential next steps. The data will also be submitted for presentation at a future medical meeting. “Platinum-resistant ovarian cancer remains one of the greatest challenges in gynecologic oncology, with patients often facing a poor prognosis and limited effective treatment options. The Phase 3 RAINFOL-02 results set a new benchmark in addressing this urgent unmet need regardless of FRα expression,” said Angeles Alvarez Secord, MD, MHSc, the study’s lead investigator for the Gynecologic Oncology Group (GOG) and Professor of Obstetrics and Gynecology at the Duke Cancer Institute. “The 71% reduction in the risk of disease progression and 57% reduction in the risk of death underscore the potential of Rina-S to change clinical practice if approved by offering a therapeutic option for a broad patient population.” Rina-S is being evaluated in a broad clinical development program spanning multiple gynecologic cancers and other solid tumors. The program includes five Phase 3 trials evaluating Rina-S in PROC (RAINFOL-02; NCT06619236), recurrent or progressive endometrial cancer (RAINFOL-03; NCT07166094), platinum-sensitive ovarian cancer (PSOC) maintenance therapy (RAINFOL-04; NCT07225270), second-line PSOC (RAINFOL-07; NCT07564141), and in first-line ovarian cancer as maintenance therapy (RAINFOL-10; NCT07859215). Additional studies include the Phase 1/2 RAINFOL-01 trial (NCT05579366) and Phase 2 trials in non-small cell lung cancer (RAINFOL-05; NCT07288177) and advanced gastrointestinal cancers (RAINFOL-09; NCT07539311). On Wednesday, October 28 at 5:00 p.m. CET/12:00 p.m. EDT, Genmab will host an investor update. To register, visit genmab.com/events-presentations. About the RAINFOL-02 Trial RAINFOL-02 (NCT06619236) is a randomized, open-label, multicenter Phase 3 study evaluating the efficacy and safety of Rina-S versus investigator’s choice chemotherapy in 582 patients with PROC regardless of FRα expression level. Patients are randomized 1:1 to receive either Rina-S 120 mg/m² on Day 1 of each three-week treatment cycle or one of four standard-of-care chemotherapy agents: paclitaxel, topotecan, PLD, or gemcitabine. The primary endpoint is investigator-assessed PFS. Key secondary endpoints are OS and objective response rate (ORR). Other secondary endpoints include PFS by blinded independent central review, duration of response, incidence of adverse events and laboratory abnormalities, time from randomization to second disease progression or death, and change from baseline in global health status/quality of life. Efficacy is evaluated in two populations. The ITT population (N = 584) includes all randomized patients, regardless of FRα expression level. The PAS (N=492), a subset of the ITT population, includes only patients with FRα expression <75% PS2+ and patients previously treated with mirvetuximab if eligible based on FRα expression ≥75% PS2+ and available in the region. About Ovarian Cancer Ovarian cancer (OC) is a major global health issue, more than 320,000 new cases diagnosed annually worldwide.^{i} It ranks as the eighth most common cancer and the eighth leading cause of cancer-related deaths among women globally.^{ii} The disease is often diagnosed at an advanced stage because its symptoms, including abdominal bloating, pelvic pain and difficulty eating, can be subtle and nonspecific.^{iii} Approximately 70-90% of women with advanced-stage OC worldwide experience a recurrence after initial treatment.^{iv} OC has a low five-year survival rate, which varies significantly by region, but generally hovers around 30-50%.^{v}^{,}^{vi} About Rinatabart Sesutecan (Rina-S; GEN1184) Rina-S (GEN1184) is an investigational ADC. It is composed of a novel human monoclonal antibody directed at FRα, a hydrophilic protease-cleavable linker, and exatecan, a TOPO1 inhibitor payload. The clinical trial program for Rina-S continues to expand, including ovarian, endometrial, and other cancers with unmet need. The safety and efficacy of Rina-S have not been established. Please visit https://clinicaltrials.gov/ for more information. About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, ADCs, immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn, X, Facebook and Instagram. Contact: Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs T: +1 609 524 0065; E: mmp@genmab.com Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E: acn@genmab.com This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab^{®}; the Y-shaped Genmab logo^{®}; Genmab in combination with the Y-shaped Genmab logo^{®}; HuMax^{®}; DuoBody^{®}; HexaBody^{®}; DuoHexaBody^{®}, HexElect^{®}, KYSO^{® }and RAINFOL™; Rina-S^{®} is a trademark of ProfoundBio, US, Co. and Genmab (Suzhou) Co., Ltd. ^{i} World Cancer Research Fund International. https://www.wcrf.org/cancer-trends/ovarian-cancer-statistics/. Accessed Oct 2025. ^{ii} World Ovarian Cancer Coalition. https://worldovariancancercoalition.org/about-ovarian-cancer/key-stats/. Accessed Oct 2025. ^{iii} Dilley, James et al. Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecologic oncology vol. 158,2 (2020): 316-322. doi:10.1016/j.ygyno.2020.05.002. ^{iv} Ovarian Cancer Research Alliance. https://ocrahope.org/patients/diagnosis-and-treatment/recurrence/ ^{v} European Institute of Women's Health. https://eurohealth.ie/policy‐brief‐women‐and‐ovarian‐cancer‐in‐the‐eu‐2018/. Accessed Oct 2025. ^{vi} American Cancer Society. Stages of Ovarian Cancer. https://www.cancer.org/cancer/types/ovarian-cancer/detection-diagnosis-staging/s urvival-rates.html. Accessed Oct 2025. Company Announcement no. 43 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 Genmab A/S Carl Jacobsens Vej 30 2500 Valby Denmark Attachments 2310266_CA43_RAINFOL-02 [1]: https://www.globenewswire.com/Tracker?data=gsTqJi6YlYwwN1wA5u4AnsluWhMdWjIc uxU9KHXjXAqGRoKNxC9MiMMbwC9Tr3MDOjJS9K0z0K6ENy4Azc-3beDD5KVT5TiFrpVWKrq0t_z4pHwX 8M3mbRGjj9iElUfb [2]: https://www.globenewswire.com/Tracker?data=gsTqJi6YlYwwN1wA5u4AnnXEECPosk1y sPMgK4IVgZWAy8BmPinKwDoENsTkcLK_MNW0BWWFulvOTZhs6BNLPAht3AOXv0aLfOnWyrHpC4Fkcpb7 M4CIDDouG-j1kJpg [3]: https://www.globenewswire.com/Tracker?data=gsTqJi6YlYwwN1wA5u4AnlWOs4fJB6S2 sEzcOzkXT9YD0rS3gfGJ8LZj2xOMPAalTXrQ68wL0Gzo_9cnJjal2vm6o06w53BLbJQd4_LPwyxjF50M -CmLbn-_CYPzD_gs [4]: https://www.globenewswire.com/Tracker?data=gsTqJi6YlYwwN1wA5u4AnqxckcCOLFiS CvUDym13C2ISz2mo3PDaA9um2G8A27BSIC_ncwcxxY7E8ExMtNI0UGGyWpH6fYTy5ma-gqbXTPbyUKpb 6_kLkxmqKYM4Q8Eu [5]: https://www.globenewswire.com/Tracker?data=gsTqJi6YlYwwN1wA5u4Anqc1nijUw7BZ 8CnbH7uOKBTNfbfenAMbJbEeyBMEdBBiYYCQ-EizAXzv0ZgSXDr7VwepsXjYPn1G-2yozFuQ6x8wYF87 cqAnAao1vkJCxyh15GpS8H25D88esIpjt5wd97krWw9raxGz8wVmsDOtjZUf1snnhdRHF6RkxfZSojp- 6NGOETADYpBioFLw9F4tRswT0hxarfACM3K502T_RBE= [6]: https://www.globenewswire.com/Tracker?data=gsTqJi6YlYwwN1wA5u4AnmsEawjhuuTa c2MmenNDxTyZ_tyBDS_9PZkDeJTXSRiO5KmWETUROB932EEXcTy7QSE1jib-rvUynRCPIeoNbUiBFXNd fY4oLpytC_OsWRY2 [7]: https://www.globenewswire.com/Tracker?data=gsTqJi6YlYwwN1wA5u4Anmvw7--6IOUH -Ou2ZS50Dz8c2fYbs6_-6JzQj3lERt7v6YSGCjmPPz_HTHTSgDZl_ytVA8-g9ZHLkGTRKEZqC-bS1WAo 9e9tBRsEQ4Svue2g [8]: https://www.globenewswire.com/Tracker?data=gsTqJi6YlYwwN1wA5u4Ann2xee6lXlAL 0CxLrXs78OSCvFkZZbBNXiNo54YycYjcrQlsMvwbR7WOI93OfbnwR7ry-FucZWLFcz-_WdO6-Gx3Hmfe 06ID8c_l1MVprATH [9]: https://www.globenewswire.com/Tracker?data=o1jpIwAXLsqk4T8k3Aa10IOPsgh6qM-C bGZH2eNUbHSe4x1OqSZE4nr5lG3uEg9mcEegHH3mSUUYg1Dcmsm91p4MyIRj64tLBEtir0Y77ERl4CkA -kFnKE934gUNsi06_8pXOCLkvy9ODjfe0cMrIg== [10]: https://www.globenewswire.com/Tracker?data=gsTqJi6YlYwwN1wA5u4Anlli7-6mbW3 _g4iorAQfJJbbiKrquQx8adllElhJgPtmlH7YjI81CzH7DIUj049n0XQ7Us3Evtsh235rnP1QnW8obZc 6Q-PulOKvlemJNbtD [11]: https://www.globenewswire.com/Tracker?data=YeWU8lqqJSQc_NMxGTNU9xBm-pq_LTj VK0Rw6Gkur29OPnGvuZa6eIXkvX70oNsJkqlVKgGKkHmM1gd8BJbYUv6M4Gvo1vG2Hgf7QXS-XDmVcdv e1dlE-SltQoaczBLb [12]: https://www.globenewswire.com/Tracker?data=9XT2RhKEDirdrs_Xg7at-0hL8yeWK7a wCILn7Vmd-JCpqGuulL3amsgYlWX4k_3agAj7C77SHX9_yJ_D7BSqQQ== [13]: https://www.globenewswire.com/Tracker?data=1EEpX6ZxEjCNfpY0BcgP-NvrAzDM7ZW bBmvFWgSxKMrVf0K-jEtfDHy17VEeBtHdaL7TqfeRx4OWFSdSOISbyZNjnubdoV2ZhmwzJKYRCzNUjH- 3jFujwWz9vgL3eFSES8cycfxoCRHF1mrsgQefMCWJlGVoR5h4fIGcYgXysnosw5EeodkK7uskCfd74Iy DRzj5tfhDLW4zl0SswuBixqz0ERiTVBPMJQ3iAvT-5zF_As8oHd0Bh9ONk_oPyDZD [14]: https://www.globenewswire.com/Tracker?data=f5YVHjc9WI3TUFgHyFXq0n3wzuow2ui 60ekIA--RQK4yksPWAXRinIHNCuiMPDj8L6-F3LPqkhW0Y1ONk7rvGImUWKB9f7gXsaE57Qb6QxaF08p -iGZg3kOTVOaRSuiKITHpAMa8PD3FmYI-yBDFs8fxr2RLctapkXAR0OgebbDCd4vmCPX25jqpCH_LLPL aAJ6bAR4mOg3TLsDOIGiLePCC8DWj7nsaZXkpRlChYSo= [15]: https://www.globenewswire.com/Tracker?data=vRifh3B1HaJtehuetukYWEqCyh4FLwn 0iYIH2efuIMdHlGfekhUwcGZYVNTmvOiWf6e-Kmq2MviJd6c1kjlISPlibw6KoD4-0STmex1E0DgMTBY efZgKSNZDPmDSkKCauVDWzAsYXCYPRI0OlWduhQ== [16]: https://www.globenewswire.com/Tracker?data=5_Zc1K3j9G2PrxtI42wsoSfd_9d95bO v3Ml7A5CyluGYxNhsV8_iTnXq-iHQQI-acqViW3QN4uKW2hdnH6UlHSTFAPJBWe5OuvuvI24z2qMaP5I YXJ8WbDxqFWm6ccPIJPrvJ4Ma0FVHC2UADUQ2_Q== [17]: https://www.globenewswire.com/Tracker?data=jniWQzOI2MZ0YcUJWT6DzH47k4Ywly_ JJl-pdwaZoxH6dpUqz4-_ADtiZBNOm5ZJZ6BuvW6S1jmf_rwKimzsdMv0g7ldtPMDrfIevawmogA= [18]: https://www.globenewswire.com/Tracker?data=mobNJsWhw_ns7jFBmGWZ1tqR7llZEN3 zZJtTI2xGSDMP7dSxjIzgTC3CDbvfkFHLyV3duh0epKvzb3PF9RFPCPoom1m6FLNkgRxImFBS1uM= [19]: https://www.globenewswire.com/Tracker?data=hfAcqR61NJRNAXxzwGMFlgBhHa47K2q edxy933s46M4RviapjoL744ipo07HzAIP9KnNJ-kfMb9xSvOV-t5sNX5vSuvkH9q9y2-K-yDTtTzyGGY 1KYzaqPvKlRZW9ODaIrnLE1juOYNx1cdw94vw9emMebCr5wT4QqKShaTSN_gxVzhIOVjFEUyhy42lSID rVZMRtkgxOUi3sZ4_IfNYmDdkazBQ_rhuXJotqPa-y7xZ80Wy33SpEXEr55VaRtAESqFLTUSnewVvdnu ESzn4cQ== [20]: https://www.globenewswire.com/Tracker?data=hfAcqR61NJRNAXxzwGMFljii69lQ0_F bcCX1wu_YfQK8CBqL3ET8J8Or071ORcyEu_7J4l3151EcTdYTo0qbHVzlXThS-EbymYULbVlAaTWlIDR 3OZqe6gy-uzrSSsF4xcXtN3w8DU-0VmgwQ05HEoE15qyb0cDxTar7BIA_NY1G_3qyYm2ojnxB8ki6SE9 tDtKQ51s0gtaDOEfGJuJ2MNqT9IR_2AfKiXBxBARqonD4hXhsZDcUNq6m2kWPYWU195jnKf92KzacGP7 n3QhYfg== [21]: https://www.globenewswire.com/Tracker?data=YeWU8lqqJSQc_NMxGTNU9yeAq-DhOPW vGqt_WZQoqaj1u5sYW5kJ5vzuPx7RUaVvdDKLRTOzSdD1nvSwEcL87UM4a3B_RhpgitmqeNZkS2_jYxV 9CKMddMTuPDRmB3GD5D2r2ekEXjbD42zBPbaKAcDo3DmaHQXUXW7eoaEVhR13v97vt5rmMIugWWsCBqP ToXB7IjYnHpx5f9EqrPtPF6XM3DFn-b_HCv7oskBq9qlc26J3PX_XTsyg74lSzYny2kJCY7zwGqqZbtW FkFtZ6qONYZQksd0bqqtwrZmfd0fqFl8yMHcIk_1wcC6DlXQRyZhiGNYHWxCRrGqRWkN1j0bTBlbWqvo d2CCoUDpj1zY628MGb-P-plg9AI0cE-O2nlZjsv_iAyvIET9QrF4dBRovalQ70IAf9ZsJJc96u-tLoB4 Hc28vM2kGJUy1SyL95MzUEaxa2PPWF2LPZUbVgg== [22]: https://www.globenewswire.com/Tracker?data=YeWU8lqqJSQc_NMxGTNU9-N9PkcTLlj ZfgrBqKvpTktHgUHjzR_eVuhbOfZ_qsnxP2J_20QIGl_Oc3lVDoDzeZxuRq5b9WpYLTznoUOh3Jah4kO T9oVWY33cOsSH0yLk2R5MQH2H2zJ3hPnVKKJs9Qh8fxn_oWDbadihfyoVJ4HMMUJQ6NnnmtihqlUFp70 xyk1NatO4AK4KV0Unhh4fK9wC8ypMnhgN4m35cZw2gRgmbkiZJHtzHWxDkzoaa5zEZxQrI_HRLDWeFjF cfAF8bG6CC7VqwhISpe-sgx_0PcKHFLsL6Wvhscp2gL4ImjSfj4qslviakFeAA3gFlzw4EKruW-IRyUs LUa0VbGe-by2UK03dA-pqt8vbizD2TEsCiBc6agHKRiFhKqhWHvsB5Zc8qqX_nAg69CSRSalvp9NBFXA K-ZxqhoGmIWlvcCA5frHaOLUhkBgHu8xbGNJ6wObkDNBjzNBZuLrkwmLZn4_9jquX8jZbOUgDGvkACIL W [23]: https://www.globenewswire.com/Tracker?data=YeWU8lqqJSQc_NMxGTNU93sF-EMAYXa DxtOFOYqtciA1sc8NYhqTHcdj3BsL09PoODMSw9VtEqnXG6WizAncZHyo5oyLCwcUlvjeyiad8lWgqpK n_g97t9GcS_a2cESSE_d7ZcgwyD8c8bx8ib7uGxe_VYxbawrw1O-2pFv4KEqKxN31ZQguks0ZERbt3gh cdMhH8A3fjT0uCHd8sDuaT5MSZqlfdtu69ZTjIg-y7kXlyPkjPz8hah1yJQdvEy6GPLHf62AMXhOkUDb ZMPPnelPKAwhtgLZuNno5LZD7SZ6F4X3BpouBuxBbNlIHpEiZWA6AhRhFMKPDmAlKPB0gk6qrSTYLkdL lkW29Z8NotTNiuVi6FpQDK9JdEFhd-F0MgYwZz19l-5077m0Vcxsvz-2JwtTv3XJb4lkE6Fh3z-zjzdw geKX-00UAeDIcqjjqK1fnkiSwXPLu7frAv4ZNeA0LolQlPZ8azhY7-z5s2BEorWXXxBf5YcxXEhrqhPA S [24]: https://www.globenewswire.com/Tracker?data=YeWU8lqqJSQc_NMxGTNU9-0h6dmZukk bwGPok6nz_4Hcn5diSL3DWeDtZLOKtqUlQ62EsDr8igtJnLKHpIXfqHgaaWyVtLBPKSbTnH9DLs_X0sT 9BBvOFxk23JyyOKRKnYJT1jqkdCBy5Gs8G5CPhAHn47diLdnKFrSSDE2YmBZerS6pPIQk1xtvVO0l4vR YMjafgEzGdzK8Ih5XooMCA62ygtqLlMsOPF4RHNMXJkE4hgkxpv1glfR0ZmACk6NyudmK_rkc3NP9Jg1 mx-RpzPyx3FoV9kcl6PRCUgkRxL0FDcrNhN6PQuicWw4kjvdlGJVbfgl_MpnW4Juq3wcW2w9q8BF4HiD EMCla1LtXFrS664TqfqYw9HxKSATBlaYH6t_4O8myU1HdcrA8BztUumH9yd_vkj66qTVdo9EPr4uyxnw ftmphNAsVneYaBT_poF_adbsHUeaBAeMiP5HHYpce9gaSlKKcby8JMdoz7iZpSGRJF53manED7z8E5BT VkASl0qIby8uGoeSC8oZvlzkF1bC8z9bWE5fq4AfZpLBSJQpF5KTCzNh87SWL9xFPC5eW65_ZH7MDViR P89e2YA== [25]: https://www.globenewswire.com/Tracker?data=YeWU8lqqJSQc_NMxGTNU9yIRF4wQsL4 mTI6tOpk4jz-Jbyh6jApVbPdhrzew-GPa0p9WVgkrdgas9Qn8V8dJHQxGffyrR335aGHldYYLh4XTcjq KBNXUr9CV6S1yXmx-OYzk9a3XXfkmMYakfzx-Ka-EN5DxOz8GHbv4WKos3xR8RnQC0xWnjMRG52gkwoL LtA6ZJj7qnMIHJOZQcd6_ig0dpZX11YHq22S9I2DzQbk1Dd8stvQSTB8nX4JIChMOpHCfXHtxIJnQjpd j48yepVnjaCIncyFyXn-y57MsrfgEJsqzldDSipPYt0EJ0GWzfSG97tJALhnnPw5OoD9QYrUIa_0piDK 3eZLxEyHLo_QxxjdQ66t0TckPv_uKsPhqrmPWL26xD4gsD7Nd-UpeBLK64QJ-CI8u98KKkAPSWdG-NxI NyB8h5fsQVz0y8QPF8zfPOKcN8BUORZ2gY2e6SsXo8Xb94H1LPmLfWKxqsX7DfpGNblD3C-JVR1ifLuV cDYGPYNChy3yqCZtEKUEys4zpEVnTnQpOjCTXLw1mtZEHyYICiBVamNcDBklzHtKBrcb9sRDR0ZURUa5 2DSWUR1iI45Kp7urMD4n-TY5zD1NHeI3Q6ZZMhCx1E2mj9-vSPH-DQNXC57FfS720-4VZLg== [26]: https://ml-eu.globenewswire.com/Resource/Download/2d64dede-243c-4f47-90fc- 3a4479eea9d8